Media Summary: Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for PCRI's Executive Director, Mark Scholz, MD, compares different treatments for men with Teal stage ( MUSC Hollings Cancer Center radiation oncologist Dr. David Marshall reviews the treatment options for

Intermediate Risk Do You Need - Detailed Analysis & Overview

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for PCRI's Executive Director, Mark Scholz, MD, compares different treatments for men with Teal stage ( MUSC Hollings Cancer Center radiation oncologist Dr. David Marshall reviews the treatment options for Medical oncologist Mark Scholz, MD answers patient's questions from our YouTube comments on the topics of active surveillance ... Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses novel tools for the management of ... Join Dr. Art Rastinehad in this enlightening session tailored for patients facing unfavorable

Dr. Mark Emberton presented “Focal Therapy for Men with Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares some results from a study which ... Dr. Larry Goldenberg, Professor & Head, Department of Urologic Sciences, and Director of Development, the Vancouver Prostate ... Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, explores the rationale and trial design of a ...

Photo Gallery

Intermediate-Risk: Do You Need Hormone Therapy With Radiation? | #MarkScholzMD #AlexScholz #PCRI
Choosing a Treatment for Intermediate Risk Prostate Cancer | Prostate Cancer Staging Guide
Intermediate Risk Prostate Cancer
Intermediate risk prostate cancer
Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13
Role of genomic profiling in the management of intermediate-risk prostate cancer
Ep 203 Intermediate Risk Pulmonary Embolism Risk Stratification, Management and Algorithm
Managing Unfavorable Intermediate Risk Prostate Cancer: Expert Guidance with Dr. Art Rastinehad
Focal Therapy for Men with Intermediate Risk Prostate Cancer
When should patients with intermediate-risk AML be indicated for alloSCT?
Understanding Prostate Cancer - Intermediate Risk
Risk Stratification in Intermediate Low Risk PE Can we do better
View Detailed Profile
Intermediate-Risk: Do You Need Hormone Therapy With Radiation? | #MarkScholzMD #AlexScholz #PCRI

Intermediate-Risk: Do You Need Hormone Therapy With Radiation? | #MarkScholzMD #AlexScholz #PCRI

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for

Choosing a Treatment for Intermediate Risk Prostate Cancer | Prostate Cancer Staging Guide

Choosing a Treatment for Intermediate Risk Prostate Cancer | Prostate Cancer Staging Guide

PCRI's Executive Director, Mark Scholz, MD, compares different treatments for men with Teal stage (

Intermediate Risk Prostate Cancer

Intermediate Risk Prostate Cancer

MUSC Hollings Cancer Center radiation oncologist Dr. David Marshall reviews the treatment options for

Intermediate risk prostate cancer

Intermediate risk prostate cancer

Intermediate

Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13

Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13

Medical oncologist Mark Scholz, MD answers patient's questions from our YouTube comments on the topics of active surveillance ...

Role of genomic profiling in the management of intermediate-risk prostate cancer

Role of genomic profiling in the management of intermediate-risk prostate cancer

Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses novel tools for the management of ...

Ep 203 Intermediate Risk Pulmonary Embolism Risk Stratification, Management and Algorithm

Ep 203 Intermediate Risk Pulmonary Embolism Risk Stratification, Management and Algorithm

How

Managing Unfavorable Intermediate Risk Prostate Cancer: Expert Guidance with Dr. Art Rastinehad

Managing Unfavorable Intermediate Risk Prostate Cancer: Expert Guidance with Dr. Art Rastinehad

Join Dr. Art Rastinehad in this enlightening session tailored for patients facing unfavorable

Focal Therapy for Men with Intermediate Risk Prostate Cancer

Focal Therapy for Men with Intermediate Risk Prostate Cancer

Dr. Mark Emberton presented “Focal Therapy for Men with

When should patients with intermediate-risk AML be indicated for alloSCT?

When should patients with intermediate-risk AML be indicated for alloSCT?

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares some results from a study which ...

Understanding Prostate Cancer - Intermediate Risk

Understanding Prostate Cancer - Intermediate Risk

Dr. Larry Goldenberg, Professor & Head, Department of Urologic Sciences, and Director of Development, the Vancouver Prostate ...

Risk Stratification in Intermediate Low Risk PE Can we do better

Risk Stratification in Intermediate Low Risk PE Can we do better

...

LB-100 in low and intermediate risk MDS

LB-100 in low and intermediate risk MDS

Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, explores the rationale and trial design of a ...